We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Jim Cramer’s best stocks for investors. In a recent episode of Mad Money, Jim Cramer ...

Bristol-Myers Squibb said it would continue to assess trial operations. Lilly and Roche said that the Phase II/III DIAN-TU trial of their amyloid beta-targeting drugs - gantenerumab and ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced the FDA approval of its new biologic treatment, EBGLYSS™ (lebrikizumab-lbkz), for patients 12 years and older... ByInvesting.com ...

Shares of Eli Lilly & Co. LLY shed 0.02% to $923.54 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.13% to 5,633.09 ...

On Thursday, Eli Lilly and Company LLY reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound.

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...